ClinicalTrials.gg
CompletedNCT04187144Updated Jul 18, 2023Results posted

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

A Phase 3 interventional study of Gepotidacin and Placebo matching nitrofurantoin in Urinary Tract Infections, sponsored by GlaxoSmithKline. Completed at 113 sites in 6 countries. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-07-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,606
Allocation
Randomized
Ages
12 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.

Enrollment
Largest of 13
1,606 · median 61
Started
2020
with 1 other
Phase 3
4 of 14
none open now
Registered
5th of 14
by date

Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 3, and was the 5th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urinary Tract Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

03

Conditions studied

  • Urinary Tract Infections

Keywords

  • Acute cystitis
  • Efficacy
  • Gepotidacin
  • Nitrofurantoin
  • Urinary Tract Infection
  • Simple cystitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is >=12 years of age at the time of signing the /assent and has a body weight >=40 kilogram (kg).
  • The participant has 2 or more of the following clinical signs and symptoms of acute cystitis with onset \<96 hours prior to study entry: dysuria, frequency, urgency, or lower abdominal pain.
  • The participant has nitrite or pyuria (greater than [>]15 white blood cell [WBC]/high-power field [HPF]) or the presence of 3 plus (+)/large leukocyte esterase) from a pretreatment clean-catch midstream urine sample based on local laboratory procedures.
  • The participant is female.
  • The participant is capable of giving signed informed consent/assent.

Exclusion criteria

Exclusion Criteria:

  • The participant resides in a nursing home or dependent care type-facility.
  • The participant has a >=40.0 kilogram per meter square (kg/m\^2) or a body mass index >=35.0 kg/m\^2 and is experiencing obesity-related health conditions such as uncontrolled high blood pressure or uncontrolled diabetes.
  • The participant has a history of sensitivity to the study treatment, or components thereof, or a history of a drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates her participation.
  • The participant is or has altered immune defenses that may predispose the participant to a higher risk of treatment failure and/or complications.
  • The participant has any of the following:

    1. Poorly controlled asthma or ; Acute severe pain,; Active peptic ulcer disease; Parkinson disease; Myasthenia gravis; Or
    2. Known acute porphyria.
    3. Any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study intervention .
  • The participant has a known glucose-6 phosphate dehydrogenase deficiency.
  • The participant has a serious underlying disease that could be imminently life threatening, or the participant is unlikely to survive for the duration of the study period.
  • The participant has acute cystitis that is known or suspected to be due to fungal, parasitic, or viral pathogens; or known or suspected to be due to Pseudomonas aeruginosa or Enterobacterales (other than Escherichia coli) as the contributing pathogen.
  • The participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis, that may interfere with the clinical efficacy assessments or preclude complete resolution of acute cystitis symptoms.
  • The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction or stricture of the urinary tract, primary renal disease (for example [e.g.], polycystic renal disease), or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract (e.g., chronic vesico-ureteral reflux, detrusor insufficiency).
  • The participant has an indwelling catheter, nephrostomy, ureter stent, or other foreign material in the urinary tract.
  • The participant who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (e.g., pyelonephritis, urosepsis), signs and symptom onset >=96 hours before study entry, or a temperature >=101.4 degree Fahrenheit (>=38 Degrees Celsius [C]), flank pain, chills, or any other manifestations suggestive of upper UTI.
  • The participant has known anuria, oliguria, or significant impairment of renal function ( \<60 milliliters per minute (mL/min) or elevated serum creatinine as determined by the investigator).
  • The participant presents with vaginal discharge at Baseline (e.g., suspected sexually transmitted disease).
  • The participant has congenital long syndrome or known prolongation of the QTc interval.
  • The participant has uncompensated heart failure.
  • The participant has severe left ventricular hypertrophy.
  • The participant has a family history of QT prolongation or sudden death.
  • The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months.
  • The participant is taking QT-prolonging drugs or drugs known to increase the risk of torsades de pointes (TdP) per the www.crediblemeds.org. "Known Risk of TdP" category at the time of her Baseline Visit, which cannot be safely discontinued from the Baseline Visit to the TOC Visit; or the participant is taking a strong cytochrome P450 enzyme 3A4 () inhibitor.
  • For any participant >=12 to \<18 years of age, the participant has an abnormal reading.
  • The participant has a QTc >450 msec or a QTc >480 msec for participants with bundle-branch block.
  • The participant has a documented or recent history of uncorrected hypokalemia within the past 3 months.
  • The participant has a known value >2 times (ULN).
  • The participant has a known value >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent [%]).
  • The participant has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice.
  • The participant has a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin.
  • The participant has received treatment with other systemic antimicrobials or systemic antifungals within 1 week before study entry.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,606 participants (actual)

Study arms

  • Experimental
    Gepotidacin

    Participants will be administered oral doses of 1500 milligrams (mg) gepotidacin plus nitrofurantoin matching placebo BID; approximately every 12 hours for 5 days.

    Drug: Gepotidacin · Drug: Placebo matching nitrofurantoin

  • Active comparator
    Nitrofurantoin

    Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.

    Drug: Nitrofurantoin · Drug: Placebo matching gepotidacin

Interventions

  • Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.

  • DrugPlacebo matching nitrofurantoin

    Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.

  • Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.

  • DrugPlacebo matching gepotidacin

    Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)

    TR at TOC (success/failure) is a measure of the overall efficacy response. A therapeutic success at TOC referred to participant who have been deemed both a microbiological success (reduction of all qualifying bacterial uropathogens recovered at Baseline \[BL\] to \<10\^3 colony forming units per milliliter \[CFU/mL\] without receiving other systemic antimicrobials \[AB\] before the TOC visit) and a clinical success (resolution of symptoms of acute cystitis present at BL and no symptoms without receiving other AB before the TOC visit \[or AB for uUTI on day of TOC visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

    Time frame: TOC visit (Days 9 to 16)

  2. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S Population

    TR at TOC (success/failure) is a measure of the overall efficacy response. A therapeutic success at TOC referred to participant who have been deemed both a microbiological success (reduction of all qualifying bacterial uropathogens recovered at Baseline \[BL\] to \<10\^3 colony forming units per milliliter \[CFU/mL\] without receiving other systemic antimicrobials \[AB\] before the TOC visit) and a clinical success (resolution of symptoms of acute cystitis present at BL and no new symptoms without receiving other AB before the TOC visit \[or AB for uUTI on day of TOC visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

    Time frame: TOC visit (Days 9 to 16)

Secondary outcomes

  1. Number of Participants With Clinical Outcome at the TOC Visit - Micro-ITT NTF-S Population

    Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution of signs and symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in total symptom score (CSS) from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).

    Time frame: TOC visit (Days 9 to 16)

  2. Number of Participants With Clinical Response at the TOC Visit - Micro-ITT NTF-S Population

    Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure at TOC.

    Time frame: TOC visit (Days 9 to 16)

  3. Number of Participants With Microbiological Outcome (MO) at the TOC Visit - Micro-ITT NTF-S Population

    Participant-level MOs at TOC were categorized as microbiological eradication (ME), microbiological persistence (MP), microbiological recurrence (MR) and unable to determine (UTD). ME at TOC was defined as all baseline qualifying uropathogens (QUP) have an outcome of eradication at TOC (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the TOC Visit). MP at TOC was defined as at least 1 QUP has an outcome of persistence (≥10\^3 CFU/mL) at TOC. MR at TOC was defined as at least 1 QUP had an outcome of recurrence and none have an outcome of persistence at TOC. UTD at TOC was defined as all QUP outcomes are UTD at TOC.

    Time frame: TOC Visit (Days 9 to 16)

  4. Number of Participants With Microbiological Response at the TOC Visit - Micro-ITT NTF-S Population

    Participant-level microbiological response at TOC was categorized as microbiological success and microbiological failure. Microbiological success at TOC was defined as all baseline qualifying uropathogens (QUP)s had a microbiological outcome of eradication at TOC visit. Microbiological failure was defined as lack of microbiological success, including those participants with UTD outcomes.

    Time frame: TOC visit (Days 9 to 16)

  5. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Follow up (FU) Visit - Micro-ITT NTF-S Population

    TR at FU was categorized as therapeutic success and therapeutic failure. A therapeutic success at FU referred to participants who have been deemed both a microbiological success (reduction of all QUPs recovered at BL to \<10\^3 CFU/mL, following microbiological eradication at the TOC visit, without receiving other AB before the FU visit) and a clinical success (resolution of signs and symptoms of acute cystitis demonstrated at the TOC visit persist at the FU visit and no new signs and symptoms, without receiving other AB before the FU visit \[or AB for uUTI on day of FU visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

    Time frame: FU visit (Days 21 to 31)

  6. Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Micro-ITT NTF-S Population

    Clinical outcomes at FU were categorized as SCR, DCR, CI, CW, CR and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at the TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. Unable to determine outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for the current infection (uUTI) prior to the assessment (unless CS or CR outcome criteria were met).

    Time frame: FU visit (Days 21 to 31)

  7. Number of Participants With Clinical Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population

    Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.

    Time frame: FU visit (Days 21 to 31)

  8. Number of Participants With Microbiological Outcome (MO) at the Follow up (FU) Visit - Micro-ITT NTF-S Population

    Participant-level MOs at FU were categorized as sustained microbiological eradication (SME), microbiological recurrence (MR), microbiological persistence (MP), delayed microbiological eradication (DME) and unable to determine (UTD). SME at FU was defined as all baseline QUPs had an outcome of sustained eradication at FU (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the FU Visit). MR at FU was defined as at least one QUP had an outcome of recurrence (≥10\^3 CFU/mL) and none had an outcome of persistence at FU. MP at FU was defined as at least one QUP had an outcome of persistence at FU. DME at FU was defined as at least one QUP had an outcome of delayed eradication and none had an outcome of persistence or recurrence at FU. UTD at FU was defined as all QUP outcomes were unable to determine at FU.

    Time frame: FU visit (Days 21 to 31)

  9. Number of Participants With Microbiological Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population

    Participant- level microbiological response at FU was categorized as microbiological success and microbiological failure. Microbiological success at FU was defined as all baseline QUPs had a microbiological outcome of sustained eradication at FU visit. Microbiological failure at FU was defined as not meeting criteria of microbiological success including those participants with UTD outcome.

    Time frame: FU visit (Days 21 to 31)

  10. Number of Participants With Clinical Outcome at the TOC Visit - Intent-to-Treat (ITT) Population

    Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in CSS from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).

    Time frame: TOC visit (Days 9 to 16)

  11. Number of Participants With Clinical Response at the TOC Visit - Intent-to-Treat (ITT) Population

    Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of signs and symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure.

    Time frame: TOC visit (Days 9 to 16)

  12. Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population

    Clinical outcomes at FU were categorized as Sustained Clinical Response (SCR), Delayed Clinical Response (DCR), CI, CW, Clinical Recurrence (CR) and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. UTD outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for current infection (uUTI) prior to assessment (unless CS or CR outcome criteria were met).

    Time frame: FU visit (Days 21 to 31)

  13. Number of Participants With Clinical Response at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population

    Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.

    Time frame: FU visit (Days 21 to 31)

  14. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

    Time frame: From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)

  15. Number of Participants With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.

    Time frame: From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)

  16. Change From Baseline in Hematology Parameters: Neutrophil Count, Lymphocyte Count, Monocyte Count, Eosinophil Count, Basophil Count and Platelet Count at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of hematology parameters: neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count and platelet count. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  17. Change From Baseline in Hematology Parameter: Hemoglobin Level

    Blood samples were collected for the analysis of hemoglobin level. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  18. Change From Baseline in Hematology Parameter: Hematocrit Level

    Blood samples were collected for the analysis of hematocrit level. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  19. Change From Baseline in Hematology Parameter: Erythrocytes (RBC) Count

    Blood samples were collected for the analysis of erythrocytes count. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  20. Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)

    Blood samples were collected for the analysis of MCH. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  21. Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)

    Blood samples were collected for the analysis of MCV. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  22. Change From Baseline in Clinical Chemistry Parameters: Serum Blood Urea Nitrogen (BUN), Glucose Non-fasting, Calcium, Chloride, Sodium, Magnesium, Phosphate, and Potassium Levels

    Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  23. Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct Bilirubin and Creatinine Levels

    Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  24. Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Levels

    Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  25. Change From Baseline in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels

    Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  26. Number of Participants With Urinalysis Dipstick Results

    Urine samples were collected for urinalysis: Urine Glucose (GLU), Urine Protein (PRO), Urine Occult Blood (BLO), Urine Ketones (KET), Urine Nitrite (NIT) and Urine Leukocyte Esterase (LEU). Baseline is defined as the latest pre-dose assessment with a non-missing value. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, Small, Moderate, Large, Positive, 50 milligram per deciliter (mg/dL), 150 mg/dL, \>=500 mg/dL, 30 mg/dL, 100 mg/dL, 200 mg/dL, 5 mg/dL, 20 mg/dL, \>=80 mg/dL indicating concentrations in the urine sample. In the row title (GLU, Baseline, Negative), GLU indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Data is presented in similar way for others parameters.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  27. Absolute Mean Values of Urine Specific Gravity

    Urine samples were collected from participants to assess urine specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  28. Absolute Mean Values of Urine Potential of Hydrogen (pH)

    Urine samples were collected from participants to assess urine pH levels. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  29. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at On-Therapy and Test of Cure Visit

    SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  30. Change From Baseline in Pulse Rate at On Therapy and Test of Cure Visit

    Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  31. Change From Baseline in Body Temperature

    Temperature was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  32. Number of Participants With Maximum Change From Baseline in Electrocardiograms (ECG) Parameter: QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB) at Worst-case Post-baseline

    Triplicate 12-lead ECGs (over an approximate 5- to 10-minute period) were performed using an ECG machine. Baseline is defined as the latest pre-dose assessment with a non-missing value. The row titles \<=450, \>450 to \<=480, \>480 to \<=500 millisecond (msec) are the values at baseline. The category titles \<= 30, 31-60, \>60 msec are the maximum change from baseline values. The maximum change from baseline value category was determined by comparing the baseline value category to the worst-case post-baseline value category for each participant, which considered unscheduled and out of visit window assessments. Data of number of participants with any change at worst-case post-baseline (maximum grade increase post-baseline) is presented.

    Time frame: Up to Day 31

  33. Number of Participants With Maximum Change From Baseline in Electrocardiograms (ECG) Parameter- QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF) at Worst-case Post-baseline

    Triplicate 12-lead ECGs (over an approximate 5- to 10-minute period) were performed using an ECG machine. Baseline is defined as the latest pre-dose assessment with a non-missing value. The row titles \<=450 msec, \>450 msec to \<=480 msec are the values at baseline. The category titles \<= 30, 31-60, \>60 msec are the maximum change from baseline values. The maximum change from baseline value category was determined by comparing the baseline value category to the worst-case post-baseline value category for each participant, which considered unscheduled and out of visit window assessments. Data of number of participants with any change at worst-case post-baseline (maximum grade increase post-baseline) is presented.

    Time frame: Up to Day 31

07

Results

Posted Jul 18, 2023

Participant flow

1605 unique participants were enrolled in the study including one participant that was randomized twice in error. This participant signed two different informed consent forms, therefore that participant was counted as enrolling twice.

Participant flow — Overall Study
MilestoneGepotidacinNitrofurantoin
Started805800
Safety population804798
Microbiological itt (micro itt) population331324
Micro-itt ntf-s population292275
Micro-itt ntf-s (ia set) population277264
Completed748759
Not completed5741
Withdrew: Lost to follow-up1211
Withdrew: Withdrawal by subject2018
Withdrew: Adverse event194
Withdrew: Physician decision53
Withdrew: Screening failure due to creatinine clearance and body mass index01
Withdrew: Protocol deviation14

Outcome measures

PrimaryNumber of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)

TR at TOC (success/failure) is a measure of the overall efficacy response. A therapeutic success at TOC referred to participant who have been deemed both a microbiological success (reduction of all qualifying bacterial uropathogens recovered at Baseline \[BL\] to \<10\^3 colony forming units per milliliter \[CFU/mL\] without receiving other systemic antimicrobials \[AB\] before the TOC visit) and a clinical success (resolution of symptoms of acute cystitis present at BL and no symptoms without receiving other AB before the TOC visit \[or AB for uUTI on day of TOC visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)
ParticipantsGepotidacinNitrofurantoin
Therapeutic Success162115
Therapeutic Failure115149
Statistical analysis
  • Gepotidacin vs Nitrofurantoin · Adjusted difference in percent: 14.6 · 95% CI 6.4 to 22.8
  • Gepotidacin vs Nitrofurantoin · 1-sided p-value for Test of Superiority · p = 0.0003 · Adjusted difference in percent: 14.6 · 95% CI 6.4 to 22.8
PrimaryNumber of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S Population

TR at TOC (success/failure) is a measure of the overall efficacy response. A therapeutic success at TOC referred to participant who have been deemed both a microbiological success (reduction of all qualifying bacterial uropathogens recovered at Baseline \[BL\] to \<10\^3 colony forming units per milliliter \[CFU/mL\] without receiving other systemic antimicrobials \[AB\] before the TOC visit) and a clinical success (resolution of symptoms of acute cystitis present at BL and no new symptoms without receiving other AB before the TOC visit \[or AB for uUTI on day of TOC visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Therapeutic Success172121
Therapeutic Failure120154
SecondaryNumber of Participants With Clinical Outcome at the TOC Visit - Micro-ITT NTF-S Population

Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution of signs and symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in total symptom score (CSS) from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Outcome at the TOC Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Clinical Resolution199175
Clinical Improvement (CI)5168
Clinical Worsening (CW)2017
Unable to Determine2215
SecondaryNumber of Participants With Clinical Response at the TOC Visit - Micro-ITT NTF-S Population

Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure at TOC.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at the TOC Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Clinical Success199175
Clinical Failure93100
SecondaryNumber of Participants With Microbiological Outcome (MO) at the TOC Visit - Micro-ITT NTF-S Population

Participant-level MOs at TOC were categorized as microbiological eradication (ME), microbiological persistence (MP), microbiological recurrence (MR) and unable to determine (UTD). ME at TOC was defined as all baseline qualifying uropathogens (QUP) have an outcome of eradication at TOC (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the TOC Visit). MP at TOC was defined as at least 1 QUP has an outcome of persistence (≥10\^3 CFU/mL) at TOC. MR at TOC was defined as at least 1 QUP had an outcome of recurrence and none have an outcome of persistence at TOC. UTD at TOC was defined as all QUP outcomes are UTD at TOC.

Time frame:
TOC Visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Outcome (MO) at the TOC Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Microbiological Eradication (ME)213158
Microbiological Persistence (MP)1331
Microbiological Recurrence (MR)1952
Unable to Determine (UTD)4734
SecondaryNumber of Participants With Microbiological Response at the TOC Visit - Micro-ITT NTF-S Population

Participant-level microbiological response at TOC was categorized as microbiological success and microbiological failure. Microbiological success at TOC was defined as all baseline qualifying uropathogens (QUP)s had a microbiological outcome of eradication at TOC visit. Microbiological failure was defined as lack of microbiological success, including those participants with UTD outcomes.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Response at the TOC Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Microbiological Success213158
Microbiological Failure79117
SecondaryNumber of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Follow up (FU) Visit - Micro-ITT NTF-S Population

TR at FU was categorized as therapeutic success and therapeutic failure. A therapeutic success at FU referred to participants who have been deemed both a microbiological success (reduction of all QUPs recovered at BL to \<10\^3 CFU/mL, following microbiological eradication at the TOC visit, without receiving other AB before the FU visit) and a clinical success (resolution of signs and symptoms of acute cystitis demonstrated at the TOC visit persist at the FU visit and no new signs and symptoms, without receiving other AB before the FU visit \[or AB for uUTI on day of FU visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Follow up (FU) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Therapeutic Success12695
Therapeutic Failure166180
SecondaryNumber of Participants With Clinical Outcome at the Follow up (FU) Visit - Micro-ITT NTF-S Population

Clinical outcomes at FU were categorized as SCR, DCR, CI, CW, CR and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at the TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. Unable to determine outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for the current infection (uUTI) prior to the assessment (unless CS or CR outcome criteria were met).

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Sustained Clinical Resolution (SCR)168154
Delayed Clinical Resolution (DCR)3435
Clinical Improvement (CI)1519
Clinical Worsening (CW)2632
Clinical Recurrence (CR)87
Unable to Determine (UTD)4128
SecondaryNumber of Participants With Clinical Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population

Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Clinical Success168154
Clinical Failure124121
SecondaryNumber of Participants With Microbiological Outcome (MO) at the Follow up (FU) Visit - Micro-ITT NTF-S Population

Participant-level MOs at FU were categorized as sustained microbiological eradication (SME), microbiological recurrence (MR), microbiological persistence (MP), delayed microbiological eradication (DME) and unable to determine (UTD). SME at FU was defined as all baseline QUPs had an outcome of sustained eradication at FU (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the FU Visit). MR at FU was defined as at least one QUP had an outcome of recurrence (≥10\^3 CFU/mL) and none had an outcome of persistence at FU. MP at FU was defined as at least one QUP had an outcome of persistence at FU. DME at FU was defined as at least one QUP had an outcome of delayed eradication and none had an outcome of persistence or recurrence at FU. UTD at FU was defined as all QUP outcomes were unable to determine at FU.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Outcome (MO) at the Follow up (FU) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Sustained Microbiological Eradication (SME)154119
Microbiological Persistence (MP)1944
Microbiological Recurrence (MR)2923
Delayed Microbiological Eradication (DME)2028
Unable to Determine (UTD)7061
SecondaryNumber of Participants With Microbiological Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population

Participant- level microbiological response at FU was categorized as microbiological success and microbiological failure. Microbiological success at FU was defined as all baseline QUPs had a microbiological outcome of sustained eradication at FU visit. Microbiological failure at FU was defined as not meeting criteria of microbiological success including those participants with UTD outcome.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Microbiological Success154119
Microbiological Failure138156
SecondaryNumber of Participants With Clinical Outcome at the TOC Visit - Intent-to-Treat (ITT) Population

Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in CSS from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Outcome at the TOC Visit - Intent-to-Treat (ITT) Population
ParticipantsGepotidacinNitrofurantoin
Clinical Resolution549517
Clinical Improvement153199
Clinical Worsening3639
Unable to Determine6745
SecondaryNumber of Participants With Clinical Response at the TOC Visit - Intent-to-Treat (ITT) Population

Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of signs and symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at the TOC Visit - Intent-to-Treat (ITT) Population
ParticipantsGepotidacinNitrofurantoin
Clinical Success549517
Clinical Failure256283
SecondaryNumber of Participants With Clinical Outcome at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population

Clinical outcomes at FU were categorized as Sustained Clinical Response (SCR), Delayed Clinical Response (DCR), CI, CW, Clinical Recurrence (CR) and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. UTD outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for current infection (uUTI) prior to assessment (unless CS or CR outcome criteria were met).

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population
ParticipantsGepotidacinNitrofurantoin
Sustained Clinical Resolution (SCR)478443
Delayed Clinical Resolution (DCR)108116
Clinical Improvement (CI)4052
Clinical Worsening (CW)5165
Clinical Recurrence (CR)2528
Unable to Determine (UTD)10396
SecondaryNumber of Participants With Clinical Response at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population

Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population
ParticipantsGepotidacinNitrofurantoin
Clinical Success478443
Clinical Failure327357
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

Time frame:
From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsGepotidacinNitrofurantoin
Number of Participants With Treatment-emergent Adverse Events (TEAEs)285200
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.

Time frame:
From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsGepotidacinNitrofurantoin
Number of Participants With Serious Adverse Events (SAEs)55
SecondaryChange From Baseline in Hematology Parameters: Neutrophil Count, Lymphocyte Count, Monocyte Count, Eosinophil Count, Basophil Count and Platelet Count at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of hematology parameters: neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count and platelet count. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Giga cells per Liter (10^9 cells/L)
Change From Baseline in Hematology Parameters: Neutrophil Count, Lymphocyte Count, Monocyte Count, Eosinophil Count, Basophil Count and Platelet Count at On Therapy and Test of Cure Visit
Giga cells per Liter (10^9 cells/L)GepotidacinNitrofurantoin
Eosinophils, Baseline0.161 ± 0.13500.163 ± 0.1331
Eosinophils, On-Therapy0.006 ± 0.08410.013 ± 0.0814
Eosinophils, Test of Cure0.015 ± 0.09060.018 ± 0.1081
Basophils, Baseline0.054 ± 0.02270.053 ± 0.0228
Basophils, On-Therapy-0.001 ± 0.01950.001 ± 0.0194
Basophils, Test of Cure0.000 ± 0.02090.001 ± 0.0183
Lymphocytes, Baseline2.091 ± 0.69542.121 ± 0.7122
Lymphocytes, On-Therapy-0.018 ± 0.4523-0.076 ± 0.5051
Lymphocytes, Test of Cure-0.010 ± 0.52920.059 ± 0.5839
Monocytes, Baseline0.529 ± 0.18030.525 ± 0.1790
Monocytes, On-Therapy-0.020 ± 0.14870.003 ± 0.1711
Monocytes, Test of Cure-0.029 ± 0.1731-0.012 ± 0.1778
Neutrophils, Baseline4.582 ± 1.88934.755 ± 1.8821
Neutrophils, On-Therapy-0.490 ± 1.6201-0.453 ± 1.7453
Neutrophils, Test of Cure-0.534 ± 2.0207-0.494 ± 1.9072
Platelets, Baseline280.3 ± 68.46287.2 ± 73.51
Platelets, On-Therapy-1.1 ± 33.03-2.5 ± 36.67
Platelets, Test of Cure6.8 ± 42.125.5 ± 58.04
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin Level

Blood samples were collected for the analysis of hemoglobin level. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Gram per Liter (g/L)
Change From Baseline in Hematology Parameter: Hemoglobin Level
Gram per Liter (g/L)GepotidacinNitrofurantoin
Baseline132.5 ± 13.25131.7 ± 14.28
On-Therapy-1.5 ± 6.74-1.9 ± 6.82
Test of Cure-1.3 ± 7.44-1.4 ± 8.33
SecondaryChange From Baseline in Hematology Parameter: Hematocrit Level

Blood samples were collected for the analysis of hematocrit level. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Percentage of hematocrit
Change From Baseline in Hematology Parameter: Hematocrit Level
Percentage of hematocritGepotidacinNitrofurantoin
Baseline0.4314 ± 0.041460.4292 ± 0.04348
On-Therapy-0.0033 ± 0.02832-0.0041 ± 0.02715
Test of Cure-0.0045 ± 0.02806-0.0029 ± 0.03194
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes (RBC) Count

Blood samples were collected for the analysis of erythrocytes count. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Tera cells per Liter (10^12 cells/L)
Change From Baseline in Hematology Parameter: Erythrocytes (RBC) Count
Tera cells per Liter (10^12 cells/L)GepotidacinNitrofurantoin
Baseline4.539 ± 0.42114.539 ± 0.4379
On-Therapy-0.046 ± 0.2309-0.060 ± 0.2513
Test of Cure-0.038 ± 0.2634-0.049 ± 0.3052
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)

Blood samples were collected for the analysis of MCH. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Picogram (pg)
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Picogram (pg)GepotidacinNitrofurantoin
Baseline29.28 ± 2.53729.09 ± 2.644
On-Therapy-0.02 ± 0.795-0.02 ± 0.820
Test of Cure-0.04 ± 0.7800.02 ± 0.917
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)

Blood samples were collected for the analysis of MCV. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Femtolitre (fL)
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)
Femtolitre (fL)GepotidacinNitrofurantoin
Baseline95.30 ± 7.19194.82 ± 7.511
On-Therapy0.26 ± 4.2870.35 ± 4.303
Test of Cure-0.15 ± 4.0490.39 ± 4.730
SecondaryChange From Baseline in Clinical Chemistry Parameters: Serum Blood Urea Nitrogen (BUN), Glucose Non-fasting, Calcium, Chloride, Sodium, Magnesium, Phosphate, and Potassium Levels

Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Clinical Chemistry Parameters: Serum Blood Urea Nitrogen (BUN), Glucose Non-fasting, Calcium, Chloride, Sodium, Magnesium, Phosphate, and Potassium Levels
millimoles per liter (mmol/L)GepotidacinNitrofurantoin
Serum Urea Nitrogen, Baseline4.742 ± 2.11074.724 ± 1.8645
Serum Urea Nitrogen, On- Therapy-0.056 ± 1.4269-0.018 ± 1.1663
Serum Urea Nitrogen, Test of Cure0.022 ± 1.40000.131 ± 1.4826
Serum Calcium, Baseline2.363 ± 0.11962.362 ± 0.1083
Serum Calcium, On-Therapy-0.010 ± 0.0950-0.018 ± 0.0944
Serum Calcium, Test of Cure-0.014 ± 0.1070-0.016 ± 0.0981
Serum Chloride, Baseline101.0 ± 3.27100.9 ± 3.27
Serum Chloride, On-Therapy0.3 ± 2.800.1 ± 2.85
Serum Chloride, Test of Cure0.4 ± 2.930.4 ± 3.02
Serum Glucose, Baseline5.590 ± 1.99805.719 ± 2.1915
Serum Glucose, On-Therapy0.230 ± 1.51200.328 ± 1.9380
Serum Glucose, Test of Cure0.215 ± 1.44120.266 ± 1.6667
Serum Magnesium, Baseline0.839 ± 0.07490.835 ± 0.0802
Serum Magnesium, On-Therapy-0.001 ± 0.0635-0.015 ± 0.0616
Serum Magnesium, Test of Cure-0.011 ± 0.0674-0.015 ± 0.0689
Serum Potassium, Baseline4.32 ± 0.4144.27 ± 0.415
Serum Potassium, On-Therapy-0.04 ± 0.417-0.03 ± 0.428
Serum Potassium, Test of Cure-0.03 ± 0.4380.00 ± 0.461
Serum Phosphate, Baseline1.141 ± 0.18281.139 ± 0.1725
Serum Phosphate, On-Therapy-0.005 ± 0.1782-0.027 ± 0.1836
Serum Phosphate, Test of Cure0.002 ± 0.1851-0.004 ± 0.1939
Serum Sodium, Baseline138.8 ± 2.64138.8 ± 2.76
Serum Sodium, On-Therapy0.0 ± 2.64-0.2 ± 2.64
Serum Sodium, Test of Cure0.2 ± 2.910.1 ± 2.91
SecondaryChange From Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct Bilirubin and Creatinine Levels

Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · micromoles per Liter (umol/L)
Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct Bilirubin and Creatinine Levels
micromoles per Liter (umol/L)GepotidacinNitrofurantoin
Serum Direct Bilirubin, Baseline4.61 ± 1.6694.47 ± 1.128
Serum Direct Bilirubin, On- Therapy-0.18 ± 1.192-0.18 ± 1.114
Serum Direct Bilirubin, Test of Cure-0.19 ± 1.0590.15 ± 1.288
Serum Total Bilirubin, Baseline6.57 ± 3.9406.56 ± 3.518
Serum Total Bilirubin, On-Therapy-0.28 ± 2.510-0.42 ± 2.672
Serum Total Bilirubin, Test of Cure-0.01 ± 2.976-0.29 ± 3.230
Serum Creatinine, Baseline58.8 ± 30.5958.1 ± 17.22
Serum Creatinine, On-Therapy0.8 ± 30.310.3 ± 10.31
Serum Creatinine, Test of Cure1.7 ± 14.001.5 ± 13.40
SecondaryChange From Baseline in Clinical Chemistry Parameters: Albumin and Protein Levels

Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · gram per Liter (g/L)
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Levels
gram per Liter (g/L)GepotidacinNitrofurantoin
Serum Albumin, Baseline45.2 ± 3.3345.2 ± 3.11
Serum Albumin, On-Therapy-0.4 ± 2.38-0.8 ± 2.56
Serum Albumin, Test of Cure-0.5 ± 2.65-0.6 ± 2.84
Serum Protein, Baseline71.5 ± 5.1271.6 ± 4.72
Serum Protein, On-Therapy-0.7 ± 3.71-1.2 ± 3.89
Serum Protein, Test of Cure-1.0 ± 4.19-1.1 ± 4.32
SecondaryChange From Baseline in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels

Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Units per Liter (U/L)
Change From Baseline in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels
Units per Liter (U/L)GepotidacinNitrofurantoin
Serum ALT, Baseline20.3 ± 20.3419.5 ± 14.66
Serum ALT, On-Therapy0.2 ± 10.8-0.1 ± 7.9
Serum ALT, Test of Cure0.4 ± 15.81-0.2 ± 9.93
Serum AST, Baseline21.0 ± 13.7220.2 ± 10.48
Serum AST, On-Therapy0.1 ± 9.830.0 ± 7.90
Serum AST, Test of Cure0.9 ± 9.89-0.5 ± 8.29
Serum ALP, Baseline81.4 ± 29.9681.7 ± 28.99
Serum ALP, On- Therapy-0.5 ± 9.61-0.1 ± 12.91
Serum ALP, Test of Cure-1.0 ± 12.00-0.4 ± 15.38
SecondaryNumber of Participants With Urinalysis Dipstick Results

Urine samples were collected for urinalysis: Urine Glucose (GLU), Urine Protein (PRO), Urine Occult Blood (BLO), Urine Ketones (KET), Urine Nitrite (NIT) and Urine Leukocyte Esterase (LEU). Baseline is defined as the latest pre-dose assessment with a non-missing value. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, Small, Moderate, Large, Positive, 50 milligram per deciliter (mg/dL), 150 mg/dL, \>=500 mg/dL, 30 mg/dL, 100 mg/dL, 200 mg/dL, 5 mg/dL, 20 mg/dL, \>=80 mg/dL indicating concentrations in the urine sample. In the row title (GLU, Baseline, Negative), GLU indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Data is presented in similar way for others parameters.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Urinalysis Dipstick Results
ParticipantsGepotidacinNitrofurantoin
GLU, Baseline, Negative751738
GLU, Baseline, 50 mg/dL45
GLU, Baseline, 150 mg/dL34
GLU, Baseline, >= 500 mg/dL2126
GLU, On-Therapy, Negative700697
GLU, On-Therapy, 50 mg/dL77
GLU, On-Therapy, 150 mg/dL15
GLU, On-Therapy, >= 500 mg/dL2328
GLU, Test of Cure, Negative686693
GLU, Test of Cure, 50 mg/dL910
GLU, Test of Cure, 150 mg/dL124
GLU, Test of Cure, >= 500 mg/dL1220
PRO, Baseline, Negative524529
PRO, Baseline, 30 mg/dL171149
PRO, Baseline, 100 mg/dL7885
PRO, Baseline, >=500 mg/dL56
PRO, On-Therapy, Negative575631
PRO, On-Therapy, 30 mg/dL11083
PRO, On-Therapy, 100 mg/dL4319
PRO, On-Therapy, >=500 mg/dL34
PRO, Test of Cure, Negative605605
PRO, Test of Cure, 30 mg/dL8888
PRO, Test of Cure, 100 mg/dL2534
PRO, Test of Cure, >=500 mg/dL10
BLO, Baseline, Positive02
BLO, Baseline, Negative345348
BLO, Baseline, Trace20
BLO, Baseline, Small229217
BLO, Baseline, Moderate128129
BLO, Baseline, Large8081
BLO, On-Therapy, Negative560520
BLO, On-Therapy, Small116161
BLO, On-Therapy, Moderate2330
BLO, On-Therapy, Large3226
BLO, Test of Cure, Negative517511
BLO, Test of Cure, Small128139
BLO, Test of Cure, Moderate4945
BLO, Test of Cure, Large2532
KET, Baseline, Negative754748
KET, Baseline, 5 mg/dL1418
KET, Baseline, 20 mg/dL117
KET, On-Therapy, Negative712699
KET, On-Therapy, 5 mg/dL1422
KET, On-Therapy, 20 mg/dL515
KET, On-Therapy, >=80 mg/dL01
KET, Test of Cure, Negative706700
KET, Test of Cure, 5 mg/dL720
KET, Test of Cure, 20 mg/dL67
NIT, Baseline, Negative552531
NIT, Baseline, Positive237252
NIT, On-Therapy, Negative694697
NIT, On-Therapy, Positive3740
NIT, Test of Cure, Negative697669
NIT, Test of Cure, Positive2258
LEU, Baseline, Negative245232
LEU, Baseline, Trace9691
LEU, Baseline, Small7580
LEU, Baseline, Moderate120116
LEU, Baseline, Large251262
LEU, Baseline, Missing21
LEU, On-Therapy, Negative510475
LEU, On-Therapy, Trace7982
LEU, On-Therapy, Small5049
LEU, On-Therapy, Moderate3457
LEU, On-Therapy, Large5874
LEU, Test of Cure, Negative526494
LEU, Test of Cure, Trace6149
LEU, Test of Cure, Small4348
LEU, Test of Cure, Moderate3559
LEU, Test of Cure, Large5477
SecondaryAbsolute Mean Values of Urine Specific Gravity

Urine samples were collected from participants to assess urine specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Ratio
Absolute Mean Values of Urine Specific Gravity
RatioGepotidacinNitrofurantoin
Baseline1.0172 ± 0.006931.0174 ± 0.00686
On-Therapy1.0176 ± 0.007161.0167 ± 0.00696
Test of Cure1.0179 ± 0.007121.0179 ± 0.00719
SecondaryAbsolute Mean Values of Urine Potential of Hydrogen (pH)

Urine samples were collected from participants to assess urine pH levels. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · pH
Absolute Mean Values of Urine Potential of Hydrogen (pH)
pHGepotidacinNitrofurantoin
pH, Baseline5.7 ± 0.85.7 ± 0.79
pH, On-Therapy5.6 ± 0.665.6 ± 0.69
pH, Test of Cure5.6 ± 0.695.7 ± 0.71
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at On-Therapy and Test of Cure Visit

SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at On-Therapy and Test of Cure Visit
Millimeters of mercury (mmHg)GepotidacinNitrofurantoin
SBP, Baseline122 ± 13.33122.7 ± 13.98
SBP, On-Therapy-1.1 ± 10.14-1.1 ± 10.72
SBP, Test of Cure-0.4 ± 11.67-1.8 ± 12.19
DBP, Baseline76.9 ± 8.1777 ± 9
DBP, On-Therapy-0.5 ± 7.30-0.6 ± 7.73
DBP, Test of Cure-0.1 ± 7.98-1.3 ± 8.37
SecondaryChange From Baseline in Pulse Rate at On Therapy and Test of Cure Visit

Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Pulse Rate at On Therapy and Test of Cure Visit
beats per minute (bpm)GepotidacinNitrofurantoin
Pulse rate, Baseline73.2 ± 9.6473.7 ± 10.32
Pulse rate, On-Therapy0.9 ± 8.241.3 ± 8.66
Pulse rate, Test of Cure1.8 ± 9.741.7 ± 9.95
SecondaryChange From Baseline in Body Temperature

Temperature was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Celsius
Change From Baseline in Body Temperature
CelsiusGepotidacinNitrofurantoin
Temperature, Baseline36.61 ± 0.34636.63 ± 0.317
Temperature, On-Therapy-0.01 ± 0.334-0.01 ± 0.372
Temperature, Test of Cure-0.01 ± 0.349-0.04 ± 0.351
SecondaryNumber of Participants With Maximum Change From Baseline in Electrocardiograms (ECG) Parameter: QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB) at Worst-case Post-baseline

Triplicate 12-lead ECGs (over an approximate 5- to 10-minute period) were performed using an ECG machine. Baseline is defined as the latest pre-dose assessment with a non-missing value. The row titles \<=450, \>450 to \<=480, \>480 to \<=500 millisecond (msec) are the values at baseline. The category titles \<= 30, 31-60, \>60 msec are the maximum change from baseline values. The maximum change from baseline value category was determined by comparing the baseline value category to the worst-case post-baseline value category for each participant, which considered unscheduled and out of visit window assessments. Data of number of participants with any change at worst-case post-baseline (maximum grade increase post-baseline) is presented.

Time frame:
Up to Day 31
Reported as:
Count of participants · Participants
Number of Participants With Maximum Change From Baseline in Electrocardiograms (ECG) Parameter: QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB) at Worst-case Post-baseline
ParticipantsGepotidacinNitrofurantoin
<= 450 msec — <=30 msec675700
<= 450 msec — 31-60 msec2312
<= 450 msec — >60 msec10
<= 450 msec — Missing4731
>450 to <=480 msec — <=30 msec4037
>450 to <=480 msec — 31-60 msec20
>450 to <=480 msec — >60 msec00
>450 to <=480 msec — Missing33
>480 to <=500 msec — <=30 msec—1
>480 to <=500 msec — 31-60 msec—0
>480 to <=500 msec — >60 msec—0
>480 to <=500 msec — Missing—0
SecondaryNumber of Participants With Maximum Change From Baseline in Electrocardiograms (ECG) Parameter- QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF) at Worst-case Post-baseline

Triplicate 12-lead ECGs (over an approximate 5- to 10-minute period) were performed using an ECG machine. Baseline is defined as the latest pre-dose assessment with a non-missing value. The row titles \<=450 msec, \>450 msec to \<=480 msec are the values at baseline. The category titles \<= 30, 31-60, \>60 msec are the maximum change from baseline values. The maximum change from baseline value category was determined by comparing the baseline value category to the worst-case post-baseline value category for each participant, which considered unscheduled and out of visit window assessments. Data of number of participants with any change at worst-case post-baseline (maximum grade increase post-baseline) is presented.

Time frame:
Up to Day 31
Reported as:
Count of participants · Participants
Number of Participants With Maximum Change From Baseline in Electrocardiograms (ECG) Parameter- QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF) at Worst-case Post-baseline
ParticipantsGepotidacinNitrofurantoin
<= 450 msec — <=30 msec721742
<= 450 msec — 31-60 msec124
<= 450 msec — >60 msec00
<= 450 msec — Missing5033
>450 to <=480 msec — <=30 msec84
>450 to <=480 msec — 31-60 msec00
>450 to <=480 msec — >60 msec00
>450 to <=480 msec — Missing01

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from the time of first dose (Day 1) through the final follow-up visit (Day 21-31). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gepotidacin0/804 (0%)5/804 (0.6%)235/804 (29.2%)
Nitrofurantoin0/798 (0%)5/798 (0.6%)119/798 (14.9%)
Most frequent serious events
Most frequent serious events
EventGepotidacinNitrofurantoin
Pyelonephritis acuteInfections and infestations0/8042/798
COVID-19Infections and infestations2/8040/798
PancreatitisGastrointestinal disorders0/8041/798
UrosepsisInfections and infestations0/8041/798
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/8041/798
Atrial fribrillationCardiac disorders1/8040/798
Abdominal painGastrointestinal disorders1/8040/798
Gastroesophageal reflux diseaseGastrointestinal disorders1/8040/798
Most frequent other events
Showing 10 of 13
Most frequent other events
EventGepotidacinNitrofurantoin
DiarrhoeaGastrointestinal disorders147/80424/798
NauseaGastrointestinal disorders65/80435/798
FlatulenceGastrointestinal disorders28/8044/798
Faeces softGastrointestinal disorders23/8044/798
HeadacheNervous system disorders21/80422/798
VomitingGastrointestinal disorders18/8047/798
DizzinessNervous system disorders18/80411/798
Urinary tract infectionInfections and infestations11/80415/798
Abdominal painGastrointestinal disorders12/8047/798
Fungal infectionInfections and infestations9/80410/798

Baseline characteristics

Participants randomly assigned to the study treatment were included in the ITT population.

Age, Continuous
Age, Continuous(Years)GepotidacinNitrofurantoinTotal
Mean48.2 ± 17.8448.4 ± 17.7248.3 ± 17.77
Age, Customized
Age, Customized(Participants)GepotidacinNitrofurantoinTotal
Less than (<) 18 years8311
More than or equal to (>=) 18 years to 50 years427430857
More than (>) 50 years370367737
Sex/Gender, Customized
Sex/Gender, Customized(Participants)GepotidacinNitrofurantoinTotal
Female8058001605
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GepotidacinNitrofurantoinTotal
Hispanic or Latino246232478
Not Hispanic or Latino5595681127
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GepotidacinNitrofurantoinTotal
American Indian or Alaska Native213
Asian5165116
Native Hawaiian or Other Pacific Islander101
Black or African American7462136
White6746681342
More than one race246
Unknown or Not Reported101
Baseline Acute Cystitis Recurrence
Baseline Acute Cystitis Recurrence(Participants)GepotidacinNitrofurantoinTotal
Recurrent Infection334338672
Non-Recurrent Infection471462933
08

Study locations

113 sites
  • GSK Investigational Site
    Birmingham, Alabama 35205, United States
  • GSK Investigational Site
    Homewood, Alabama 35209, United States
  • GSK Investigational Site
    Huntsville, Alabama 35801, United States
  • GSK Investigational Site
    Gilbert, Arizona 85296, United States
  • GSK Investigational Site
    Peoria, Arizona 85381-3689, United States
  • GSK Investigational Site
    Phoenix, Arizona 85015-1104, United States
  • GSK Investigational Site
    La Mesa, California 91942, United States
  • GSK Investigational Site
    Modesto, California 95350-5365, United States
  • GSK Investigational Site
    Northridge, California 91324, United States
  • GSK Investigational Site
    Sacramento, California 95821, United States
  • GSK Investigational Site
    Valencia, California 91355-5319, United States
  • GSK Investigational Site
    Washington, District of Columbia 20011, United States
  • GSK Investigational Site
    Apollo Beach, Florida 33572, United States
  • GSK Investigational Site
    Boynton Beach, Florida 33435, United States
  • GSK Investigational Site
    Clearwater, Florida 33761, United States
  • GSK Investigational Site
    Coconut Creek, Florida 33063, United States
  • GSK Investigational Site
    Gainesville, Florida 32607, United States
  • GSK Investigational Site
    Hialeah, Florida 33013, United States
  • GSK Investigational Site
    Lake Worth, Florida 33461, United States
  • GSK Investigational Site
    Leesburg, Florida 34748, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33135, United States
  • GSK Investigational Site
    Miami, Florida 33155, United States
  • GSK Investigational Site
    Miami, Florida 33186-2178, United States
  • GSK Investigational Site
    Orlando, Florida 32810, United States
  • GSK Investigational Site
    Ormond Beach, Florida 32174, United States
  • GSK Investigational Site
    Palm Springs, Florida 33406, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33026-4383, United States
  • GSK Investigational Site
    Plant City, Florida 33563, United States
  • GSK Investigational Site
    Sweetwater, Florida 33172, United States
  • GSK Investigational Site
    Tampa, Florida 33614, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Blackfoot, Idaho 83221, United States
  • GSK Investigational Site
    Boise, Idaho 83704, United States
  • GSK Investigational Site
    Meridian, Idaho 83642, United States
  • GSK Investigational Site
    Hanover, Maryland 21076, United States
  • GSK Investigational Site
    Fall River, Massachusetts 02723, United States
  • GSK Investigational Site
    Butte, Montana 59701, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68510, United States
  • GSK Investigational Site
    East Orange, New Jersey 07018-1502, United States
  • GSK Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • GSK Investigational Site
    Mount Laurel, New Jersey 08054, United States
  • GSK Investigational Site
    Bronx, New York 10456, United States
  • GSK Investigational Site
    Brooklyn, New York 11229, United States
  • GSK Investigational Site
    New York, New York 10016-7313, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Cary, North Carolina 27518, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28412, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Fargo, North Dakota 58104, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45215, United States
  • GSK Investigational Site
    Columbus, Ohio 43213, United States
  • GSK Investigational Site
    Columbus, Ohio 43214, United States
  • GSK Investigational Site
    Columbus, Ohio 43231, United States
  • GSK Investigational Site
    Dayton, Ohio 45424, United States
  • GSK Investigational Site
    Eugene, Oregon 97404, United States
  • GSK Investigational Site
    Bala-Cynwyd, Pennsylvania 19004, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Lancaster, South Carolina 29720, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Milan, Tennessee 38358, United States
  • GSK Investigational Site
    New Tazewell, Tennessee 37824-1409, United States
  • GSK Investigational Site
    Austin, Texas 78735, United States
  • GSK Investigational Site
    Austin, Texas 78744 -1645, United States
  • GSK Investigational Site
    Houston, Texas 77087, United States
  • GSK Investigational Site
    Katy, Texas 77450, United States
  • GSK Investigational Site
    Mesquite, Texas 75149, United States
  • GSK Investigational Site
    Missouri City, Texas 77459, United States
  • GSK Investigational Site
    North Richland Hills, Texas 76180, United States
  • GSK Investigational Site
    Plano, Texas 75024, United States
  • GSK Investigational Site
    San Antonio, Texas 78209, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    San Antonio, Texas 78251, United States
  • GSK Investigational Site
    Bountiful, Utah 84010, United States
  • GSK Investigational Site
    Saint George, Utah 84790, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84107, United States
  • GSK Investigational Site
    Richmond, Virginia 23225, United States
  • GSK Investigational Site
    Richmond, Virginia 23235, United States
  • GSK Investigational Site
    Maroubra, New South Wales 2035, Australia
  • GSK Investigational Site
    Sydney, New South Wales 2010, Australia
  • GSK Investigational Site
    Tarragindi, Queensland 4121, Australia
  • GSK Investigational Site
    Gabrovo, 5300, Bulgaria
  • GSK Investigational Site
    Haskovo, 6300, Bulgaria
  • GSK Investigational Site
    Kyustendil, 2500, Bulgaria
  • GSK Investigational Site
    Montana, 3400, Bulgaria
  • GSK Investigational Site
    Pleven, 5800, Bulgaria
  • GSK Investigational Site
    Ruse, 7000, Bulgaria
  • GSK Investigational Site
    Shumen, 9700, Bulgaria
  • GSK Investigational Site
    Sofia, 1606, Bulgaria
  • GSK Investigational Site
    Stara Zagora, 6000, Bulgaria
  • GSK Investigational Site
    Targovisthe, 7700, Bulgaria
  • GSK Investigational Site
    Aurangabad, 431001, India
  • GSK Investigational Site
    Chandrapur, 442402, India
  • GSK Investigational Site
    Hyderabad, 500004, India
  • GSK Investigational Site
    Mumbai, 400022, India
  • GSK Investigational Site
    Nagpur, 440003, India
  • GSK Investigational Site
    Nagpur, 440015, India
  • GSK Investigational Site
    Nashik, 422101, India
  • GSK Investigational Site
    New Delhi, 110062, India

Showing the first 100 of 113 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Perry C, Hossain M, Powell M, Raychaudhuri A, Scangarella-Oman N, Tiffany C, Xu S, Dumont E, Janmohamed S. Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants. Infect Dis Ther. 2022 Dec;11(6):2297-2310. doi: 10.1007/s40121-022-00706-9. Epub 2022 Oct 21. PubMed 36271314 ↗
  • Fishman C, Caverly Rae JM, Posobiec LM, Laffan SB, Lerman SA, Pearson N, Janmohamed S, Dumont E, Nunn-Floyd D, Stanislaus DJ. Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0048322. doi: 10.1128/aac.00483-22. Epub 2022 Oct 18. PubMed 36255258 ↗
  • Scangarella-Oman NE, Hossain M, Hoover JL, Perry CR, Tiffany C, Barth A, Dumont EF. Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0149221. doi: 10.1128/AAC.01492-21. Epub 2022 Jan 3. PubMed 34978887 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Dec 2022, 31 months.

Results were first posted in Jul 2023, 7 months after primary completion.

Of 23 industry-sponsored phase 3 interventional studies under Urinary Tract Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 31 months is above that.

Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2019
First posted
Dec 5, 2019
StartActual
Apr 23, 2020
Primary completionActual
Dec 1, 2022
CompletionActual
Dec 1, 2022
Results first posted
Jul 18, 2023
Last update
Jul 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04187144
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Apr 23, 2020
Primary completion
Dec 1, 2022
Completion
Dec 1, 2022
Results posted
Jul 18, 2023
Last update
Jul 18, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion